Novo Partners for AI Drug Discovery… Again; Novo Two FIH Obesity Studies; Zealand Initiates Ph2 Enicepatide + Petrelintide Obesity Study
Here is a brief preview of this blast: Three cardiometabolic-related news items have been observed: nference entered into a partnership with Novo for cardiometabolic research (view press release); Novo initiated two FIH obesity studies (view CT.gov record; view CT.gov record); and Zealand initiated the Ph2 ZYNERGY study of petrelintide + enicepatide for obesity (view press release). Below, FENIX provides highlights and insights for the respective news items.

